The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response
- PMID: 26065421
- PMCID: PMC4465930
- DOI: 10.1371/journal.pntd.0003749
The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response
Abstract
Dengue is the most prevalent mosquito-borne viral disease worldwide. Yet, there are no vaccines or specific antivirals available to prevent or treat the disease. Several dengue vaccines are currently in clinical or preclinical stages. The most advanced vaccine is the chimeric tetravalent CYD-TDV vaccine of Sanofi Pasteur. This vaccine has recently cleared Phase III, and efficacy results have been published. Excellent tetravalent seroconversion was seen, yet the protective efficacy against infection was surprisingly low. Here, we will describe the complicating factors involved in the generation of a safe and efficacious dengue vaccine. Furthermore, we will discuss the human antibody responses during infection, including the epitopes targeted in humans. Also, we will discuss the current understanding of the assays used to evaluate antibody response. We hope this review will aid future dengue vaccine development as well as fundamental research related to the phenomenon of antibody-dependent enhancement of dengue virus infection.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.J Virol. 2018 May 29;92(12):e00440-18. doi: 10.1128/JVI.00440-18. Print 2018 Jun 15. J Virol. 2018. PMID: 29593041 Free PMC article.
-
Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.Lancet Infect Dis. 2021 Apr;21(4):517-528. doi: 10.1016/S1473-3099(20)30767-2. Epub 2020 Nov 16. Lancet Infect Dis. 2021. PMID: 33212067 Clinical Trial.
-
Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.Hum Vaccin Immunother. 2014;10(10):2853-63. doi: 10.4161/21645515.2014.972131. Hum Vaccin Immunother. 2014. PMID: 25483647 Free PMC article. Clinical Trial.
-
From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.Vaccine. 2011 Sep 23;29(42):7229-41. doi: 10.1016/j.vaccine.2011.06.094. Epub 2011 Jul 13. Vaccine. 2011. PMID: 21745521 Review.
-
Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.Cell Host Microbe. 2021 Jan 13;29(1):13-22. doi: 10.1016/j.chom.2020.12.011. Cell Host Microbe. 2021. PMID: 33444553 Review.
Cited by
-
Avoiding Regions Symptomatic of Conformational and Functional Flexibility to Identify Antiviral Targets in Current and Future Coronaviruses.Genome Biol Evol. 2016 Dec 31;8(11):3471-3484. doi: 10.1093/gbe/evw246. Genome Biol Evol. 2016. PMID: 27797946 Free PMC article.
-
Designing a polytope for use in a broad-spectrum dengue virus vaccine.J Taibah Univ Med Sci. 2017 Dec 15;13(2):156-161. doi: 10.1016/j.jtumed.2017.11.002. eCollection 2018 Apr. J Taibah Univ Med Sci. 2017. PMID: 31435318 Free PMC article.
-
DENV-Mimetic Polymersome Nanoparticles Bearing Multi-Epitope Lipopeptides Antigen as the Next-Generation Dengue Vaccine.Pharmaceutics. 2022 Jan 10;14(1):156. doi: 10.3390/pharmaceutics14010156. Pharmaceutics. 2022. PMID: 35057051 Free PMC article.
-
Drivers of Inter-individual Variation in Dengue Viral Load Dynamics.PLoS Comput Biol. 2016 Nov 17;12(11):e1005194. doi: 10.1371/journal.pcbi.1005194. eCollection 2016 Nov. PLoS Comput Biol. 2016. PMID: 27855153 Free PMC article.
-
Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses.PLoS Negl Trop Dis. 2016 Oct 20;10(10):e0005071. doi: 10.1371/journal.pntd.0005071. eCollection 2016 Oct. PLoS Negl Trop Dis. 2016. PMID: 27764114 Free PMC article.
References
-
- European Centre for Disease Prevention and Control. Annual epidemiological report 2012.guidelines for the surveillance of invasive mosquitoes in Europe.stockholm: ECDC; 2012
-
- Gubler DJ, Meltzer M. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv Virus Res. 1999;53: 35–70. - PubMed
-
- World Health Organization. Fact sheet: Dengue and severe dengue. Http://www.who.int/mediacentre/factsheets/fs117/en/index.html. 2012;March 2013: 1.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical